Keros Therapeutics 

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$388
$37
$83
$143
Gross Profit
388
-269
-194
-104
EBITDA
-58,657
-50,133
-48,206
-39,996
EBIT
-50,439
-48,483
-40,243
Net Income
-52,956
-45,257
-43,114
-40,243
Net Change In Cash
388
37
83
143
Free Cash Flow
-30,886
-40,111
-45,506
-26,000
Cash
530,684
405,863
442,443
331,147
Basic Shares
36,103
36,103
29,447
30,126

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$151
$20,000
$20,100
$2,500
Gross Profit
-664
-1,615
19,202
-605
EBITDA
-152,177
-103,063
-56,373
-44,922
EBIT
-152,992
-104,678
-57,271
-45,527
Net Income
-152,992
-104,680
-58,744
-45,361
Net Change In Cash
151
20,000
20,100
2,500
Cost of Revenue
49,006
-34,622
258,856
Free Cash Flow
-126,972
-71,303
-63,172
-37,188
Cash
331,147
279,048
230,042
265,876
Basic Shares
29,447
25,241
23,333
15,506

Earnings Calls

Quarter EPS
2024-09-30
-$1.41
2024-06-30
-$1.25
2024-03-31
-$1.21
2023-12-31
-$1.34